Literature DB >> 3941394

Stabilization of antagonist binding to cardiac muscarinic acetylcholine receptors by gallamine and other neuromuscular blocking drugs.

J Nedoma, S Tucek, A F Danilov, S A Shelkovnikov.   

Abstract

The effects of neuromuscular blocking drugs and muscarinic agonists and antagonists on the dissociation of [3H]quinuclidinylbenzilate ([3H]QNB) from muscarinic receptors was studied on rat atrial homogenates. In typical experiments the investigated drug was added to the homogenate equilibrated with [3H]QNB and the amount of undissociated [3H]QNB receptor complexes was measured 40 min later. The antagonists atropine and pirenzepine, agonists carbamoylcholine and methylfurmethide and neuromuscular blockers pancuronium, d-tubocurarine and decamethonium caused a concentration-dependent dissociation of [3H]QNB from the receptors, which may be explained by their competition with [3H]QNB for the same (primary) binding sites. In accordance with this, these drugs did not affect the dissociation of [3H]QNB elicited by an excess of atropine, which indicates that the kinetics of dissociation of the [3H]QNB receptor complex remained unchanged in their presence. Neuromuscular blockers alcuronium, gallamine and to a lesser degree tercuronium differed from the other drugs in that 1) their effect on [3H]QNB dissociation was biphasic, being higher at their low (10(-6) to 10(-5) M) than at their high concentrations (10(-4) to 10(-3) and that 2) at high concentrations they strongly inhibited the dissociation of [3H]QNB receptor complexes elicited by the excess of atropine. Their behavior may be rationalized by assuming that at low concentrations they bind to the primary binding site making rebinding of once dissociated [3H]QNB molecules improbable (competitive mechanism), whereas at high concentrations they also act on a secondary (allosteric) binding site stabilizing the [3H]QNB receptor complexes by slowing their off-kinetics.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941394

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Drugs and receptors. An overview of the current state of knowledge.

Authors:  T Kenakin
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

2.  Subtype-selective inhibition of [methyl-3H]-N-methylscopolamine binding to muscarinic receptors by alpha-truxillic acid esters.

Authors:  M Lysíková; K Fuksová; T Elbert; J Jakubík; S Tucek
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 3.  Rational design of dualsteric GPCR ligands: quests and promise.

Authors:  Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

4.  Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists.

Authors:  M Lysíková; Z Havlas; S Tucek
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

5.  Inhibition of acetylcholine muscarinic M(1) receptor function by the M(1)-selective ligand muscarinic toxin 7 (MT-7).

Authors:  M C Olianas; C Maullu; A Adem; E Mulugeta; E Karlsson; P Onali
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

6.  Two populations of muscarinic binding sites in the chick heart distinguished by affinities for ligands and selective inactivation.

Authors:  J Jakubík; S Tucek
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 7.  Allosteric Modulation of Muscarinic Acetylcholine Receptors.

Authors:  Jan Jakubík; Esam E El-Fakahany
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.